MDT-637: Phase I data

The double-blind, placebo-controlled, U.S. Phase I Study MDT-637-CP-102 trial in healthy volunteers showed that multiple ascending-doses of MDT-637 were well tolerated with no significant adverse events or clinically significant changes in lung function reported. Additionally, MicroDose said MDT-637 was present in the respiratory tract at levels that were several orders of magnitude higher than concentrations necessary to inhibit clinical isolates of RSV in vitro. ...